Preventing ovarian hyperstimulation syndrome by inhibiting the effects of vascular endothelial growth factor.

J Reprod Med

Department of Obstetrics and Gynaecology, School of Medicine, Queen's University Belfast, Institute of Clinical Science, Grosvenor Road, Belfast, Northern Ireland, BT12 6BJ.

Published: April 2003

Objective: To evaluate whether inhibiting the effects of vascular endothelial growth factor can prevent the ovarian hyperstimulation syndrome.

Study Design: Rates were hyperstimulated with follicle-stimulating hormone injections. On the final day of stimulation, the rats were randomized to receive or not receive exogenous soluble fmslike tyrosine kinase (sFlt-1). Forty-eight hours later capillary permeability was determined by measuring the concentration of Evans blue dye (EB) in peritoneal irrigation fluid 3 minutes after an intravenous injection of EB.

Results: The peritoneal EB level was statistically significantly lower in the hyperstimulated group, which received the sFlt-1, than in the stimulation-only group.

Conclusion: sFlt-1 may play a therapeutic role in management of the ovarian hyperstimulation syndrome by specifically inhibiting the effects of vascular endothelial growth factor.

Download full-text PDF

Source

Publication Analysis

Top Keywords

ovarian hyperstimulation
12
inhibiting effects
12
effects vascular
12
vascular endothelial
12
endothelial growth
12
growth factor
12
hyperstimulation syndrome
8
syndrome inhibiting
8
preventing ovarian
4
factor objective
4

Similar Publications

Objectives: This study aimed to investigate the correlation of ovarian sensitivity index (OSI) and clinical parameters in IVF treatments.

Methods: IVF data files between January 2011 and December 2020 in a single unit were included. The primary outcome measure was the correlation between the OSI and clinical pregnancy and live birth rates.

View Article and Find Full Text PDF

Background: The gonadotropin-releasing hormone antagonist (GnRH-ant) protocol is associated with few oocytes retrieved, few mature oocytes and poor endometrial receptivity. Omission of GnRH-ants on trigger day seems unlikely to induce preovulation and may improve outcomes in the GnRH-ant protocol. This study aimed to systematically evaluate the effects of GnRH-ant cessation on trigger day on in vitro fertilisation outcomes following the GnRH-ant protocol.

View Article and Find Full Text PDF

Objective: The association between vitamin D deficiency and ovarian reserve-specific outcomes of assisted reproductive technology (ART) remains uncertain. This study aimed to investigate the role of ovarian reserve in the association between basal serum vitamin D levels and ART outcomes in patients undergoing controlled ovarian hyperstimulation (COH).

Methods: A total of 1,333 infertile women undergoing COH cycles were retrospectively analyzed.

View Article and Find Full Text PDF

Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis.

Hum Reprod

December 2024

Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Study Question: Is the probability of pregnancy different between women using biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART?

Summary Answer: Meta-analysis of eight randomized clinical trials (RCTs) suggests that live birth, clinical, and ongoing pregnancy rates are significantly lower with biosimilars of follitropin alfa compared to the originator.

What Is Known Already: All biosimilars of follitropin alfa have received regulatory approval by demonstrating non-inferiority in the number of retrieved oocytes compared to the originator. Nevertheless, the most clinically relevant outcome in ART for both clinicians and patients is live birth.

View Article and Find Full Text PDF

Background: Most cases of ovarian hyperstimulation syndrome (OHSS) are caused by infertility treatment using human menopausal gonadotropin (HMG) and human chorionic gonadotropin (hCG). OHSS is widely known to have a "spoke-wheel" appearance on imaging, presenting as bilateral symmetric enlargement of ovaries with multiple cysts of varying sizes. When this spoke-wheel appearance is observed in patients not undergoing infertility treatment, tumor-derived hormones such as follicle-stimulating hormone (FSH) and hCG should be measured.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!